VPRO press release below:
Strategic Partnership between Viropro and University of Montreal
Synergy for the Production of Therapeutic Proteins
Sep 28, 2006 7:00:00 AM
Copyright Business Wire 2006
MONTREAL--(BUSINESS WIRE)--
Dr. Jean-Marie Dupuy, President and CEO of Viropro Inc. or "The Company" (OTCBB: VPRO) is pleased to announce the signing of an agreement with the Laboratory of Veterinary and Food Biotechnology of the Faculty of Veterinary Medicine (LVFB) of St. Hyacinthe (University of Montreal, Quebec). The collaborative agreement aims at developing therapeutic products within the University of Montreal laboratory, an ultramodern infrastructure that conforms to good manufacturing practices (GMP).
This agreement will create a manufacturing process on an industrial scale designed to produce clinical lots of therapeutic proteins. As well, the agreement will enable international clients of Viropro to accelerate the registration of products with regulatory agencies. For Viropro, the strength of this agreement is to bring about a more rapid development of clinical lots for their clients. This will accelerate the marketing of the newly developed products by 12 to 18 months.
"I am extremely delighted by the partnership agreement with the Laboratory of Veterinary and Food Biotechnology," states Dr. Jean-Marie Dupuy. "This strategic alliance will further strengthen those agreements which Viropro has concluded with other technological partners, such as the Biotechnological Research Institute of Canada."
According to Dr. Mario Jacques, Vice-Dean of Research and Higher Education at the Faculty of Veterinary Medicine, "a partnership such as this will enable university research scientists to offer their scientific support and technological expertise towards the realization of promising projects, while broadening for eventual industrial application the knowledge and validation of bio-processes developed at the university."
About Viropro Inc.
Viropro Inc. conducts operations mainly through its subsidiary Viropro International Inc. whose head office is located in Montreal, Canada. Viropro is a rapidly expanding biopharmaceutical company specializing in the transfer of its technologies for industrial production of biogeneric therapeutic proteins, excluding vaccines, for the treatment of various diseases including cancer, diabetes, hepatitis and multiple sclerosis. The company's principal objective is to bring about the transfer of technology to pharmaceutical companies in those parts of the world where demand for high quality biopharmaceutical products has not been met, such as in South America, Asia and Africa. To expand its range of expertise in biopharmaceuticals excluding therapeutic vaccines, Viropro has concluded strategic alliances with various scientific and business partners renowned in national and international spheres. Viropro's business model rests on a strategy aimed at generating recurrent short and long-term revenues, all while maximizing the value of assets and profits of its shareholders.
For more information on Viropro Inc., please visit our website on www.viropro.com
Viropro Inc. Safe Harbor Statement
Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward-looking statements". Forward-looking statements in this release may be identified through the use of such words as "expects", "anticipates", "estimates", "believes", or statements indicating certain actions "may", "could", or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors.
DIRECT ALL INQUIRIES TO:
Investor Relations: investors@viropro.com
Source: Viropro Inc.
----------------------------------------------
Viropro Inc.
Investor Relations:
Andre Bedard
514-731-8776
investors@viropro.com
